Wedbush Raises Earnings Estimates for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (TSE:FRX) – Stock analysts at Wedbush lifted their Q2 2025 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a research note issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.14). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q3 2025 earnings at $0.56 EPS, Q4 2025 earnings at $0.15 EPS, FY2025 earnings at $0.59 EPS, FY2026 earnings at $1.47 EPS and FY2027 earnings at $2.57 EPS.

Fennec Pharmaceuticals Stock Performance

FRX opened at C$9.50 on Friday. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The business’s 50-day moving average price is C$8.25 and its two-hundred day moving average price is C$8.38. The company has a market capitalization of C$183.20 million, a price-to-earnings ratio of -160.93 and a beta of 0.25. Fennec Pharmaceuticals has a 1 year low of C$5.65 and a 1 year high of C$10.14.

Insider Activity at Fennec Pharmaceuticals

In related news, Director Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction dated Friday, April 4th. The stock was sold at an average price of C$7.46, for a total transaction of C$74,550.00. Over the last quarter, insiders have sold 18,978 shares of company stock valued at $157,818. 16.20% of the stock is owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.